ReviewFrontiers in neuroscience2026
Tracing melanin-concentrating hormone function: decades of memory research and emerging links to Alzheimer's disease.
Review in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanin-concentrating hormone (MCH) is a hypothalamic neuropeptide classically implicated in the regulation of energy homeostasis, sleep-wake cycle and motivated behaviors. Over the last 30 years, an increasing amount of evidence has revealed a complex, non-linear role in memory processing. In this mini-review, we summarize experimental findings on the multifaceted influence of MCH on memory, highlighting how this neuropeptide can promote consolidation by improving synaptic efficacy, induce the forgetting of hippocampus-dependent memories during REM sleep or negatively regulate memory formation. We also discuss emerging evidence linking MCH dysregulation to the pathophysiology of Alzheimer's disease (AD). Early interest in MCH as a cerebrospinal fluid biomarker has been superseded by non-invasive blood assays. Recent data, however, suggest therapeutic potential and a unique pathological vulnerability. While emerging evidence suggests MCH somata may show early resilience, their axonal projections are severely compromised by amyloid pathology. Ultimately, tau pathology appears to drive late-stage somatic degeneration and reduced activation during REM sleep. Importantly, activating surviving MCH neurons has been shown to restore sleep architecture in preclinical models, offering a potential therapeutic target for sleep disturbances. In conclusion, decades of basic memory research together with human and preclinical studies identify the MCH system as an important neuromodulatory network for understanding the memory and sleep alterations characteristic of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.